Growth Hormone Withdrawal in Mid-Puberty: No Impact on Near Adult Height in Adolescents With Transient Idiopathic GHD
Authors' conclusion
In adolescents with transient IIGHD, rhGH treatment can be stopped at mid-puberty. These findings support reducing rhGH treatment duration, lowering patient burden and health-care costs.
Study context
- Population
- Adolescents with childhood idiopathic isolated GHD (GH peak 1.7–10 µg/L) who tested GH sufficient (GH peak >6.7 µg/L) at mid-puberty; 95 male (75%); pediatric endocrinology departments, 2017–202499% completed
- Participants
- 127 adolescents
- Exposure
- Recombinant human GH (rhGH) continuation vs discontinuation from mid-puberty until near adult height (NAH)
- GHcontn = 44
- GHstopn = 83
- Outcome
- NAH-SDS minus target height (TH)-SDS
- Follow-up
- Mean NAH
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
NAH-SDS minus TH-SDS
GHcont
−0.17
mean · SD 0.60
GHstop
−0.18
mean · SD 0.62
P = 0.96
Observational data: associations, not effects.
Secondary outcomes
Total pubertal growth (from start of puberty), males
P = 0.25
Total pubertal growth (from start of puberty), females
P = 0.90
Mean
| Outcome | GHcont | GHstop | P value |
|---|---|---|---|
| NAH-SDS · mean NAH | −0.91 (SD 0.76) | −0.78 (SD 0.76) | P = 0.35 |
Predicted vs attained height gain
- Predicted vs attained height gain based on the prediction model did not differ between groups
Original publication
Growth Hormone Withdrawal in Mid-Puberty: No Impact on Near Adult Height in Adolescents With Transient Idiopathic GHD. J Clin Endocrinol Metab. Published 15 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →